Oral hypomethylating agents: beyond convenience in MDS

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myelodysplastic syndromes (MDS) traditionally require frequent intravenous infusion therapy.
• Monthly clinic visits for infusions pose significant burdens on patient quality of life, finances, and transportation.
• This necessitates exploring alternative treatment modalities for improved patient management.

Observation:

• Oral hypomethylating agents (HMAs) have been developed as a more accessible treatment option.
• Two distinct oral HMAs, oral azacitidine and decitabine-cedazuridine, have distinct pharmacokinetic and toxicity profiles.
• These agents are being investigated in clinical trials for both lower- and higher-risk MDS.

Findings:

• Oral HMAs have the potential to significantly reduce the frequency of clinic visits.
• Improved convenience may lead to better patient adherence to long-term MDS treatment.
• Differential pharmacokinetic profiles suggest tailored applications based on MDS risk stratification.

Implications:

• Oral HMAs can alleviate the substantial burden of frequent infusions on patients.
• Enhanced treatment adherence facilitated by oral HMAs may improve long-term outcomes in MDS.
• The development of oral HMAs represents a significant advancement in MDS patient care and accessibility.